Section Arrow
FHTX.NASDAQ
- Foghorn Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2025/06/03 09:44 EDT
Last
 4.17
0 (0.00%)
Day High 
4.17 
Prev. Close
4.17 
1-M High
4.67 
Volume 
1.01K 
Bid
4.11
Ask
4.42
Day Low
4.17 
Open
4.17 
1-M Low
3.565 
Market Cap 
232.44M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 4.16 
20-SMA 4.19 
50-SMA 3.97 
52-W High 10.25 
52-W Low 2.9448 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.29/-1.31
Enterprise Value
260.51M
Balance Sheet
Book Value Per Share
-1.11
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
22.60M
Operating Revenue Per Share
0.58
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TRAWTraws Pharma Inc2.2191+0.7991+56.27%-- 
REVBRevelation Biosciences Inc0.9844+0.1614+19.61%-- 
RENBRenovaro0.4039+0.114+39.32%-- 
NCNANuCana plc0.0403+0.0023+6.05%-- 
AGENAgenus4.3124+0.1824+4.42%0.14PE
Quotes are at least 15-min delayed:2025/06/03 09:44 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.